Alterity Therapeutics Secures Key US Patent for Lead Asset - Alterity Therapeutics (NASDAQ:ATHE)

Alterity Therapeutics secured a USPTO patent for ATH434, extending market protection for its neurodegenerative drug candidate to 2045.

Raccontata dabenzinga.com